
XtalPi inks $250M pact with Lilly after Pfizer success
XtalPi is lining up another Big Pharma collaboration following its work with Pfizer on Paxlovid and a recent tie-up with Janssen. This time the AI and robotics biotech is helping Eli Lilly design new drug candidates for an undisclosed target.
The Shenzhen-based startup said Tuesday that the deal could line XtalPi’s coffers with $250 million. The more than 1,000-employee company plans to deploy its artificial intelligence chops and robotics platform to “deliver a novel compound,” which Lilly will be responsible for investigating and developing commercially. XtalPi’s small-molecule drug discovery platform includes 500 AI models and quantum physics algorithms. The biotech was born out of a group of MIT quantum physicists in 2014.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.